OliX PharmaceuticalsInc

OliX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. Its pipeline includes OLX101A for skin scars, OLX104C for androgenic alopecia, OLX301A for age-related macular degeneration, OLX702A for metabolic dysfunction-associated steatohepatitis, OLX703A for hepatitis, and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals, a development collaboration with the Korea Institute of Technology, and a research collaboration with the University of Virginia. Formerly known as Biomolecular Therapeutics Inc., OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.